This is for oncology but there are similar kninds of "rules of thumb" for other non-revenue biotechs coming into phase 3 results.
Over 300 million market cap is good!
https://www.thestreet.com/story/12696926/1/the-feuerstein-ratain-rule-update-still-perfect-predicting-small-cap-cancer-drug-failure.html